Kendall J. Schick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kendall J. Schick has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Manriquez Roman
T Cell Engineering, Mayo Clinic, Rochester, MN
34 shared publications - Michelle J. Cox
T Cell Engineering, Mayo Clinic, Rochester, USA
34 shared publications - Neil E. Kay
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
34 shared publications - Sameer A. Parikh
Division of Hematology, Mayo Clinic, Rochester, USA
34 shared publications - Elizabeth L. Siegler
T Cell Engineering, Mayo Clinic, Rochester, Minnesota
33 shared publications - Ismail Can
Division of Hematology, Mayo Clinic, Rochester, USA
32 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells